The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBraveheart Inv Regulatory News (BRH)

Share Price Information for Braveheart Inv (BRH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.50
Bid: 6.00
Ask: 7.00
Change: 0.00 (0.00%)
Spread: 1.00 (16.667%)
Open: 6.50
High: 6.50
Low: 6.50
Prev. Close: 6.50
BRH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of options

27 Mar 2023 07:00

RNS Number : 2333U
Braveheart Investment Group plc
27 March 2023
 

27 March 2023

Braveheart Investment Group plc

("Braveheart" or the "Company")

 

Grant of options

 

Braveheart Investment Group (AIM: BRH), announces that, on 24 March 2023, the Company granted options over a total of 2,950,000 ordinary shares of 2p each in the Company ("Ordinary Shares") to the Directors and a service provider to the Company (the "Options"). The Options have been granted pursuant to the Company's share option plan adopted on 16 December 2020. 

 

In order to be eligible to receive new EMI options, Vivian Hallam, Executive Director, has, on 24 March 2023, surrendered 523,808 EMI options previously granted to him on 14 October 2021 and that had an exercise price of 31.5p.

 

In aggregate, 2,900,000 Options have been granted to Directors of the Company, as follows:

 

Name

No. options over Ordinary Shares previously held

No. Options granted

No. options over Ordinary Shares surrendered

Resultant holding of options over Ordinary Shares held

Percentage of the current issued share capital of the Company

Trevor Brown

1,500,000

1,250,000

-

2,750,000

4.3

Vivian Hallam

2,500,000

1,250,000

523,808

3,226,192

5.1

Susan Hagan

50,000

200,000

-

250,000

0.4

Qu Li

0

200,000

-

200,000

0.3

 

The Options granted to Vivian Hallam are EMI options and the Options granted to Trevor Brown, Susan Hagan and Qu Li are unapproved options. The exercise price of the Options is 7.75p, being the closing mid-market price of an Ordinary Share on 24 March 2023, the date of grant. The Options will vest from 27 March 2024 and be exercisable up to 27 March 2033, subject to continued employment. The Options granted to Trevor Brown and Vivian Hallam, as Executive Directors of the Company, have an additional performance related vesting criteria that the closing mid-market price of an Ordinary Share must exceed 9.6875p (being a 25% premium to the Option exercise price) for 10 business days out of a consecutive 30 business day period.

 

Following the grant of the Options and surrender of historic options held by Viv Hallam, the Company now has options outstanding over a total of 7,022,192 Ordinary Shares, equivalent to 11.0% of the Company's current issued share capital.

 

Further details of the Options can be found in the Notification of Dealing Form below.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Trevor Brown

Chief Executive Officer

Vivian Hallam

Executive Director

Susan Hagan

Non-Executive Director

Qu Li

Non-Executive Director

 

 

2

 

Reason for the notification

 

a)

 

Position/status

 

See 1a) above 

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Braveheart Investment Group plc

b)

 

LEI

 

2138006HQ3COMU626I61

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 2 pence each in Braveheart Investment Group plc

 

GB00B13XV322

b)

 

Nature of the transactions

 

Grant of options over ordinary shares

c)

 

Price(s) and volume(s)

 

 

Price: Exercise price of 7.75p per option

 

Trevor Brown

1,250,000

Vivian Hallam

1,250,000

Susan Hagan

200,000

Qu Li

200,000

d)

 

Aggregated information

- Aggregated volume

- Price

- Principal amount

 

N/A

 

e)

 

Dates of the transaction

 

24 March 2023

f)

Place of transaction

Outside a trading venue

 

For further information:

 

Braveheart Investment Group plc

Tel: 01738 587555

Trevor Brown CEO

Allenby Capital Limited (Nominated Adviser and Joint Broker)

Tel: 020 3328 5656

David Worlidge / James Reeve / George Payne

Peterhouse Capital Limited (Joint Broker)

Tel: 020 7469 0936

Duncan Vasey / Lucy Williams

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDGGDXXUDDGXL
Date   Source Headline
10th Apr 20247:00 amRNSHolding(s) in Company
27th Mar 202412:03 pmRNSHolding(s) in Company
6th Mar 20247:00 amRNSAcquisition of further interest in Autins Group
4th Mar 202411:48 amRNSInvestment update – Paraytec Limited
4th Mar 20247:00 amRNSCompletion of sale of Phasefocus
9th Jan 202412:00 pmRNSHolding(s) in Company
22nd Dec 20231:30 pmRNSHolding(s) in Company
22nd Dec 20237:00 amRNSPortfolio update - Proposed sale of Phasefocus
15th Dec 202311:41 amRNSInvestment update - Paraytec Limited
15th Dec 202310:16 amRNSReplacement: Half-year Report
14th Dec 20237:00 amRNSHalf-year Report
29th Nov 20237:00 amRNSInvestment update - Paraytec Limited
14th Nov 20239:02 amRNSHolding(s) in Company
17th Oct 20237:00 amRNSInvestment update – Paraytec Limited
10th Oct 202311:15 amRNSHolding(s) in Company
8th Sep 20237:00 amRNSInvestment update – Kirkstall Limited
8th Sep 20237:00 amRNSBlock admission six monthly return
21st Aug 20237:00 amRNSFurther investment in Phasefocus Holdings Limited
28th Jul 20232:25 pmRNSInvestment update on Paraytec Limited
28th Jul 202311:54 amRNSResult of AGM
5th Jul 20237:00 amRNSPosting of annual report and notice of AGM
4th Jul 20237:00 amRNSHolding(s) in Company
3rd Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
31st May 20237:00 amRNSInvestment update – Phasefocus Holdings Limited
3rd May 20237:00 amRNSUpdate on investments
24th Apr 202310:49 amRNSHolding(s) in Company
27th Mar 20237:00 amRNSGrant of options
13th Mar 20239:34 amRNSHolding(s) in Company
9th Mar 20237:00 amRNSBlock admission six monthly return
10th Feb 20231:26 pmRNSHolding(s) in Company
30th Jan 20234:37 pmRNSHolding(s) in Company
16th Jan 20237:00 amRNSDirector/PDMR Shareholding
10th Jan 20237:00 amRNSOperational update
22nd Dec 20229:14 amRNSHolding(s) in Company
19th Dec 20229:25 amRNSDirector/PDMR Shareholding
19th Dec 20229:11 amRNSAcquisition of interest in Image Scan Holdings plc
13th Dec 20224:37 pmRNSHolding(s) in Company
15th Nov 20223:09 pmRNSHolding(s) in Company
7th Nov 20227:00 amRNSDirector/PDMR Shareholding
28th Oct 20227:00 amRNSHalf-year Report
21st Oct 202210:33 amRNSHolding(s) in Company
20th Oct 20221:59 pmRNSAcquisition of further interest in Autins
5th Oct 20223:15 pmRNSHolding(s) in Company
5th Oct 202212:28 pmRNSAcquisition of further interest in Aukett Swanke
30th Sep 20225:00 pmRNSTotal Voting Rights
20th Sep 20227:00 amRNSPlacing and subscription to raise £750,000
9th Sep 20227:00 amRNSBlock admission six monthly return
6th Sep 20227:00 amRNSHolding(s) in Company
2nd Sep 202211:20 amRNSHolding(s) in Company
1st Sep 20227:00 amRNSAcquisition of further interest in Aukett Swanke

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.